Oranogenesis Holdings (ORGO) PT Raised to $6 at Cantor Fitzgerald

Cantor Fitzgerald analyst Ross Osborn raised the price target on Oranogenesis Holdings (NASDAQ: ORGO) to $6.00 (from $5.00) while maintaining a Overweight rating.

The analyst commented, “the company” reported “a 4Q24 beat and establishing strong 2025 guidance. Specifically, ORGO reported total revenue of $126.7 million (Cantor $114.4 million / FactSet Consensus $107.2 million), representing YoY growth of ~27%, driven by a ~27% increase in advanced wound care products to $118.6 million. Turning to guidance, ORGO established 2025 revenue guidance in the range of $480.0 million to $535.0 million (Cantor $448.0 million / FactSet consensus $481.2 million), representing YoY growth of ~flat to 11%.”

Also, “Guidance assumes a challenging 1H25 with a significant improvement following the skin substitute LCD implementation in April. Putting it all together, we believe ORGO is set up to take wound market share, given ~180 skin substitute products will now be prohibited to receive reimbursement from Medicare, with ORGO's Affinity, Apligraf, and Dermagraft products on the covered list for reimbursement.

You May Also Be Interested In

• Intuitive Machines Inc. (LUNR) PT Lowered to $32 at Cantor Fitzgerald, Reaffirms Overweight Rating
• Freedom Broker Upgrades Serve Robotics (SERV) to Buy
• Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters